A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.
Trial Number
NCT00263822 (ClinicalTrials.gov Identifier)Contact Person
Status
Completed
Disease Site
Ovarian